header-frame
NOVEL GENE EDITING

Imagine A Better CRISPR

CRISPR CAS9

TRADITIONAL GENE EDITING: ONE OF THE MOST COMMON TECHNIQUES FOR GENE EDITING

  • Single edits
  • 50-60 base pair edits or gene inserts
  • 1 strain per experiment
  • 8 weeks per experiment on average to: synthesize DNA, perform transformations, and assay results
  • High error rate

XENOARRAY™ BY XENOMICS

NEXT GENERATION GENE EDITING: ADDING GENES, ENZYMES AND PATHWAYS

  • Parallel edits
  • 8,000 base pair gene inserts
  • 3k unique cell strains in parallel
  • Single 8 week experiment is comparable to 460 years of iterative CRISPR
  • Genetic search space of over 160 quadrillion unique combinations of promoters, terminators, and/or genes
  • 1 to 8 unique genes
R&D

Core Technologies

WETWARE
SCALED GENOME EDITING
XenoArray™ generates up to 3,000 unique cell lines within a search space of 160 quadrillion combinations. The XenoArray™ is ideal for Gene Knock-Ins: Adding Genes, Enzymes & Pathways
  • Parallel edits
  • 8,000 base pair gene inserts
  • 3,000 unique cell strains in parallel
  • Single 8 week experiment is comparable to 460 years of iterative CRISPR
  • Genetic search space of over 160 quadrillion unique combinations of promoters, terminators, and/or genes
  • 1 to 8 unique genes
HARDWARE
MICROFLUIDIC CELL HANDLING & ANALYSIS
We anticipate deploying a combination of commercially available equipment and custom microfluidic tooling to streamline lab processes, cell handling, and analysis.
  • Through a combination of commercially available equipment and custom microfluidic tooling, Xenomics anticipates having a system that can:
  • Ferment 10-15k strains in parallel for 72 hours per microfluidic chip
  • Assay 9k strains per day for results
  • Accelerate our design-build-test-learn model from weeks to days
SOFTWARE
BIOLOGICAL DATABASES, AND AI
Xenomics is working to streamline strain engineering by expanding upon previously published metabolomics databases and leveraging AI to improve our design-build-test-learn model.
  • Antibodies, enzymes, and other proteins with enhanced properties
  • Deep learning AI with atomic level precision
  • Target Databases:
  • Organisms library
  • DNA - Genomics
  • RNA - Transcriptomics
  • Proteins - Proteomics
  • Biochemical – Metabolomics
  • Biological Phenotype
OUR PEOPLE

Leadership Team

alternative

David Preiner

FOUNDER & CEO
  • Harvard University (Ext. BLA candidate) - Biology, Engineering Sciences, Nanotechnology
  • Boston Children's Hospital
  • State of MN
  • Bootstrapped 3 multi-million dollar startups
alternative

John Harrold, PhD

CO-FOUNDER & COO
  • MIT - Instructor Material Science & Engineering, Fellow
  • Harvard University - Physics Postdoc
  • Rutgers - PhD. B.S. B.A. Chemical Physics, Biochemistry
  • Led 30 person lab, 4 startups, 2 funded by NSF, 2 patents
alternative

Sophie Ni, PhD

CO-FOUNDER & CPO
  • MIT -PhD. Material Science, Engineering, Energy Applications
  • Nanyang Technological University - Engineering
  • Yamada, USA, managed US$83M P&L to deliver 43% growth in 3yrs
  • Startup co-founder
  • Forbes 30 under 30
alternative

Ryan Hubbard, MD

CO-FOUNDER & CMO
  • Mayo School of Graduate Medical Education - Resident Physician in Physical Medicine and Rehabilitation, Resident Internal Medicine
  • Georgetown University, M.D
  • Former Medical Instructor at Mayo Clinic (2016-2017)
  • 25+ Publications, Posters, and Oral Presentations
  • Sports Team Physician
alternative

Dan Kriznic, CPA, CA

CO-FOUNDER & CFO
  • Created Over $1 Billion in Enterprise Value
  • $700 Million in Exits
  • $243 Million in M&A Transactions
  • $175 Million in Financings
  • 9 Public Listings
alternative

Natasha Collins, CPA, CA

VP FINANCE
  • Over a Decade of Experience Advising Public and Private Companies
  • $180MM of M&A Transactions
  • 2 Public Listings
alternative

Olivier Roussy Newton

VP BUSINESS DEVELOPMENT
  • Founder of Hive Blockchain and Latent Capital
  • Raised Over 400M in the Past 2 Years
alternative

David Wood, PhD LLB

ADVISOR
  • Partner at Borden Ladner Gervais LLP, PhD in Biochemistry, Lawyer and Patent Agent
  • Co-chair of the BLG Cannabis Industry Focus Group
  • Legal practice focuses on intellectual property and regulatory law – regulatory practice entirely focused on cannabis (including hemp) and restricted drugs (psilocybin, MDMA, LSD and others)
NEWSLETTER

Stay Updated With The Latest News

I've read and agree to Xenomics's written Privacy Policy and Terms Conditions
footer-frame